Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.

@article{Maust2015AntipsychoticsOP,
  title={Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.},
  author={D. Maust and Hyungjin Myra Kim and L. Seyfried and C. Chiang and J. Kavanagh and L. Schneider and H. Kales},
  journal={JAMA psychiatry},
  year={2015},
  volume={72 5},
  pages={
          438-45
        }
}
IMPORTANCE Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear. OBJECTIVE To determine the absolute mortality risk increase and number needed to harm (NNH) (ie, number of patients who receive treatment that would be associated with 1 death) of antipsychotic, valproic acid and its derivatives, and antidepressant use in patients with dementia relative… Expand
Association Between Antipsychotics and All-Cause Mortality Among Community-Dwelling Older Adults.
TLDR
While significant increase in mortality was attributable to the diagnosis of dementia, the addition of antipsychotics resulted in added mortality risk among all patients, and antipsychotic medications should be used cautiously in all older adults, not only those with dementia. Expand
Association of Benzodiazepines and Antidepressants With 180-Day Mortality Among Patients With Dementia Receiving Antipsychotic Pharmacotherapy: A Nationwide Registry-Based Study.
TLDR
Clinicians should be cautious when considering the combination of antipsychotics and benzodiazepines in patients with dementia initiating antipsychotic drug treatment, because the results cannot prove causality, and there may be residual confounding. Expand
Potentially Inappropriate Prescriptions of Antipsychotics for Patients With Dementia
TLDR
Increased age, being treated with memantine, simultaneously presenting with anxiety, depression, and psychotic disorders, and concomitantly receiving anticonvulsants, bronchodilators and benzodiazepines were associated with a greater probability of being prescribed antipsychotics. Expand
Update on Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia
Neuropsychiatric symptoms (NPS) commonly occur in dementia and are a major source of burden and distress for both patients and their caregivers. Nonpharmacological treatments are often of limitedExpand
Benefits and harms of atypical antipsychotics for agitation in adults with dementia
TLDR
Clinicians may recommend atypical antipsychotics with continuous monitoring of behavioral symptoms, informing patients and their families or caregivers of the significant risk of adverse effects and baseline risk of acute myocardial infraction and bone fractures. Expand
Pimavanserin: Potential Treatment For Dementia-Related Psychosis
TLDR
The study uses a relapse-prevention design with the endpoint of time-to-relapse of psychosis to evaluate the long-term efficacy and safety of pimavanserin as a potential treatment for hallucinations and delusions of dementia-related psychosis. Expand
Patterns of psychotropic prescribing and polypharmacy in older hospitalized patients in Ireland: the influence of dementia on prescribing
TLDR
Polypharmacy and psychotropic drug use is highly prevalent in older Irish hospitalized patients, especially in people with dementia, and hospital admission presents an ideal time for medication reviews in PwD. Expand
Anticonvulsants for behavioral and psychological symptoms in dementia: protocol for a systematic review
TLDR
This systematic review will help clinicians and policy makers compare the efficacy of anticonvulsants compared to antidepressants and antipsychotics as well as identify areas which will need further study. Expand
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia
TLDR
The evidence base for using SSRI medications in the treatment of NPS is growing, but the applicability of research findings to the utility of SSRIs in general in routine clinical practice is not entirely clear at this point. Expand
A review on mortality risks associated with antipsychotic use in behavioral and psychologic symptoms of dementia (BPSD)
TLDR
An updated overview of the publications available on mortality data and risks associated with antipsychotic dose and duration of use is provided to allow clinicians to better make judgment calls on assessing risks and benefits when treating BPSD with an antipsychotics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Risk of mortality among individual antipsychotics in patients with dementia.
TLDR
There may be differences in mortality risks among individual antipsychotic agents used for treating patients with dementia, and the use of valproic acid and its derivatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry associated risks. Expand
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
TLDR
Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives. Expand
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
TLDR
The use of antipsychotic medications, both conventional and atypical, was not associated with either time to nursing home admission or time to death after adjustment for relevant covariates, and the presence of psychiatric symptoms was linked to increased risk of institutionalization and death. Expand
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
TLDR
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease. Expand
Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.
TLDR
Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms and the association between mortality and antipsychotics is not well understood. Expand
Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
TLDR
Conventional antipsychotic medications are at least as likely as atypical agents to increase the risk of death among elderly persons and that conventional drugs should not be used to replace atypicals agents discontinued in response to the FDA warning. Expand
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
  • L. Schneider, K. Dagerman, P. Insel
  • Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
TLDR
Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone. Expand
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
TLDR
Among elderly patients, the risk of death associated with conventional antipsychotic medications is comparable to and possibly greater than therisk of deathassociated with atypical antipsychotics medications. Expand
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
TLDR
In patients with Alzheimer's disease who had psychosis or agitation that had responded to ris peridone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. Expand
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
TLDR
Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of cITALopram may limit its practical application at the dosage of 30 mg per day. Expand
...
1
2
3
4
...